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tlolubkov. Nicholas A kuorco. Katherine M. Iletre. Thorna:. .I. 
Ryan, David P. Faxon and the NllLBl co-investigators, hoslon 
University Medical Center, Boston. MA 
The long- term outcome of patients (pts) after unsuccessful (1’) 
but uncomplicat@d (no death. MI or emergency (:.411(i) I’TCA h:rs 
not been previously reported, and may be influenced b> thr 
presrnccl or absence of coronary c?‘)iiaterals. Acc!jrdin:;l.\ . WC 
assessed 3 )ear outcome after unrompllcated single Iesrcrl 
- I’l’(!A III 10s (I tirtd XX . ' surcrssful (S) pts. Comp:irrtI I.1 b pl.5. r: 
pts were mort likelq to ha\t nrulti -vessel disf*ase (GOk ; s ;?J%. 
p<.Ol). prior Ml (44% vs 33953. pt.05). LV ejec:trotl fr:ic LI: II \o(l’k 
(24% vs 164. 1~C.05) and atcernptrd I’TCA of a total oc~Iusi(~ll 
(4%0 b’s 109r. r,;.O(~i ). I! pts itice also morF liht*lh. to urirkricl 
cur]) elt :IIL~ IiAbl; (19% \b ick. pi,0011 and L~a\t. alrvil:a rti 
hospit;r: d6chsrgc (Wk vs - “PI. p;.(J(ll), Al 11 3’(\:if I\liiorL -II,). 
death (5% cs 4%) and Ml (6% bs 6%) rates PerC similiir (r=)\L:. 
for I; :rnd S pLs. I, pts rtBquir(bti mciro CA 
whereas repeal I”I’CA was more rommon 
p<.OOl). At 3 ye:rrh, 45% of II [bts afld 8 
free (p=NS) In U pIs In uhom coronary collateral fina 11, t tad 
target leston was ldentifit!d on the pre-PTVA anRlol:r:unt; 
(n=67). Ml did no1 occur (Ok us 13?b in U $1.~ althout 
collaterals ln=4RI. p<.Ol) 
Conclusions: 
I) c!oronary collaterals provide protection against future> M: 
after I: J’TL’A. 
2) 1: pts frequently require CAIIC. but despite more st’\ (Irk: 
coronary disease and L\ dysfunction acheike a simillar Icn::- 
term outcome to pts after S I’I’CA. 
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OUTCOME WITH MULTILES~ON AND MULTIVESSEL 
CORONARY ANGIOPLASTY OF 3 OR MORE SITES 
James Vacek, M.D., FACC., 
Thomas Rosamond, M.D., Loren Berenbom, M.D., F.A.C.C., Paul 
Kramer, M.D., FA.C.C., Wayne Robuck, MA., MS., Mid America 
Heart Institute, St. Luke’s Hospital, Kansas City, Missouri 
Data describing multilesion and multivessel percutaneous transluminal 
coronary angioplasty (PTCA) is limited, and most series include 
patients who had ooly 2 sites dilated. We describe a large series of 
patients who had PTCA of a3 lesions. 272 patients had either 1 
vessel multilesion (Group A, n=62) or multivesseUmultilesion (Group 
B, n-210) PTCA. An overall mean of 3.5 lesions/patient (A=3.1, 
B~3.7 Pe.01) were dilated with a success rate of 94.8% (A=96.3, 
B=94.5, P=NS). Between groups P=NS for age (64*10 overall), sex 
(73% male overall), prior Ml (31% A, 34% B), prior coronary artery 
bypass grafting (CABG) (16% A, 24% B), ejection f?action (mean 
54% vs 52%). 
Over mean follow-up of 58 weeks the need for re-cath was the same 
(43% both groups) with documented restenosis (% of patients) 
similar (27% A, 32% B). Need for CABG was similar (15% vs 
19% P=NS) as was death (9.7% vs 8.1% P=NS). 
We conclude: “true” multilesion and multivessel PTCA is possible 
with success and restenosis rates similar to 1 asd 2 lesion results. 
Results for several lesions in 1 vs h 2 vessels is remarkably similar. 
However, need for re-cath and CABG is high, as is mortality over 
relatively short follow up periods. These results may compare 
unfavorably with those of CABG. 
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LONG-TERM OUTCOME OF PATIENTS WITH DEPRESSED LEFT 
VENTRICULAR FUNCTION UNDERGOING PERCUTANEOUS TRANSL 
CORONARY ANGIOPLASTY-THE NHLBI PTCA REGISTRY 
David R. Holmes Jr., Katherine M. Detre, David 0. 
Williams, Kenneth M. Kent, Spencer 8. King, Wan-Lin Yeh, 
Ann Steenkiste, Mayo Clinic, Rochester, MN, USA 
An increasing number of pts with depressed LV function 
(EF<40%) are undergoing coronary angioplasty (PTCA); to 
evaluate their initial and longer-term outcome, the 
1985-1986 NHLBI PTCA Reaistry exoerience was assessed. 
There were 126 pts with 
and 1329 pts with EF>40 
undergoin$ elective PTCA. Pts kdergoing PTtA for acute 
myocardial infarction (MI) were excluded. Gr 1 pts had a 
(0.8 vs 0.8%). nonfatal 
surgery (4.8 vs 3.3%). 
rate at 3 year follow-up were: 
No Event and No 
No Event or Improved Angina 
Death GL41 Gr 2 95 coo1 G:7’ Gr 2 89 t.001 
Death/MI 72 87 t.001 81 c.001 
Death/MI/surgery 63 75 <.Ol 56; 70 LO1 
1) Pts with depressed LV function have simiiir success 
and complication rates compared to pts with presence of 
normal LV function undergoing PTCA. 2) Pts with 
depressed LV function have increased cardiac events 
during follow-up although the majority are improved. 
8:30 
AN ABNORMALITY IN THE CATALYT:r, SUBUNIT OF ADENYLATE 
CYCLASE CHARACTERIZES PRESSURE-OVERLOADED, FAILING HUMAN 
VENTRICULAR MYOCARDIUM. Bichael R. Bristow, Lisa Skerl, 
Patti Larrabee, Wayne Minobe, Randy Rasmussen, Robert 
Ginsburg. University of Utah, Salt Lake City, UT 
Most infcwnation on the adrenergic neuroeffector 
mechanism (ANM) in the failing human heart (FHH) has 
been derived from studies with idiopathic dilated 
cardiomyopathy (IDC). Recent data in ischemic and 
valvular cardiomyopathy indicate that model-dependent 
differences in ANM abnormalities may exist in the FHH. 
In the current study right ventricular (RV) myocardium 
failing due to marked pressure overload (PA 
pressure-57+,4 m&g, RA-9+1.4 mmHg) derived from 13 
subjects of average age 34.9k2.2 yrs undergoing heart- 
lung transplantation for primary pulmonary hypertension 
(PPH) was compared to RVs with a similar degree of 
failure @A-9.7+1.1 mmHg) taken from 50 subjects with 
IDC, age 38.922.3 yrs. Adrenergic receptors, the 
adrenergic neurotransmitters (NTS) norepinephrine (NE) 
and neuropeptide Y (NPY), adenylate cyclase (AC) 
stimulation and muscle contraction in isolated 
trabeculae (tissue M. Cntxn) were mecsured. Results f 
SEM were: (*-pc.05) 
Crour, Receotors Tissue AC stimulat ‘ic n Tissue 
fmol/mg FTS. g,,&, pmol/cAMP/mg/min Y. Cntxn 
81 -&- NEnNpy !a.*& MnZ+ 
;r23.9 19.1 *190 *30 
Ca*+ IS0 
PPH 
22.5 23.4 264 211 *0:6 
*23.0 *831 1061 
+3.6 2107 +_233 
IDC 34.0 17.8 756 66 9.1 40.0 1366 1222 
22.5 21.4 2108 f10 21.3 k2.9 +109 flO0 
Conclusion: PPH RV differs from IDC RV by exhibiting 1) 
greater adrenergic neurotransmitter depletion; 2) 
greater B, receptor down-regulation; and 3) an abnor- 
mality of the catalytic subunit of adenylate cyclase, 
which has not been previously described in FFH. 
